Home › Cardiotoxicity › NCT04262830
Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
CATCH-HF: Cardiotoxicity Assessment Through Comprehensive Heart Imaging to Predict Heart Failure
Who can join
Ages 13 to 39 · All sexes
Full eligibility criteria
Inclusion Criteria: * English and Spanish speaking male and female subjects, ages 13-39 years old * Diagnosis of cancer at age \<22 years * Previously treated with anthracyline therapy for cancer, with diagnosis at least two years prior. Exclusion Criteria: * Patients who have a contraindication to cardiac MRI, including the presence of non-MRI compatible metallic implants. * Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia. * Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus). * Pregnancy (at the time of enrollment).
About the study
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) are commonly given to treat pediatric cancer, and carry a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
What is being tested
- Cardiac magnetic resonance imaging (MRI) (diagnostic test)
- Accelerometer physical activity monitoring (other)
Sponsor: Hari Narayan · Participants: 150 · Started: Sep 30, 2019
Contact the study team
- Hari Narayan, MD · Phone: 8589665855 / 8589331718
- Cesar Vasquez · Phone: 8589331718
Official record on ClinicalTrials.gov — NCT04262830
Locations in the U.S.
| California | Rady Children's Hospital, San Diego |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.